Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $3,487,247 | $1,643,375 |
| General and administrative | 1,738,006 | 1,578,442 |
| Total operating expenses | 5,225,253 | 3,221,817 |
| Income (loss) from operations | (5,225,253) | (3,221,817) |
| Interest income (loss) | 1,332,203 | 596,845 |
| Net income (loss) | (3,893,050) | (2,624,972) |
| Other comprehensive income (loss): |
Document
FAQ
- What is Monopar Therapeutics's R&D?
- Monopar Therapeutics (MNPR) reported R&D of $3.49M in Q1 2026.
- How has Monopar Therapeutics's R&D changed year-over-year?
- Monopar Therapeutics's R&D increased by 112.2% year-over-year, from $1.64M to $3.49M.
- What is the long-term trend for Monopar Therapeutics's R&D?
- Over 4 years (2021 to 2025), Monopar Therapeutics's R&D has grown at a 11.1% compound annual growth rate (CAGR), from $6.49M to $9.9M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Monopar Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude